Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know
As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025